Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
The Lancet. Haematology|June 19, 2019
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trialMatthew S Davids, Danielle M Brander, Haesook T Kim, et al.
Blood Cancer Journal|February 5, 2025
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestryCecilia Bonolo de Campos, Chantal E McCabe, Laura A Bruins, et al.
Transplantation and Cellular Therapy|June 13, 2025
Clinical practice recommendations on the role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy in patients with chronic lymphocytic leukemia on behalf of the American Society for Transplantation and Cellular TherapyMohamed A Kharfan-Dabaja, Ambuj Kumar, Javier Pinilla-Ibarz, et al.
Haematologica|February 9, 2018
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysisAnthony R Mato, Chadhi Nabhan, Meghan C Thompson, et al.
The Lancet. Oncology|January 17, 2017
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F Seymour, Shuo Ma, Danielle M Brander, et al.
British Journal of Haematology|November 5, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemiaToby A Eyre, Lindsey E Roeker, Christopher P Fox, et al.
Leukemia|July 21, 2021
Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African AmericansGeffen Kleinstern, J Brice Weinberg, Sameer A Parikh, et al.
The Lancet. Oncology|July 10, 2022
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trialConstantine S Tam, Jennifer R Brown, Brad S Kahl, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 19, 2023
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International StudyMazyar Shadman, Beenish S Manzoor, Kavita Sail, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 13, 2026
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026William G Wierda, Jennifer Brown, Jeremy S Abramson, et al.
Pageof 6